Sorafenib inhibits cancer side population cells by targeting c‑Jun N‑terminal kinase signaling.

Sorafenib is a systemic chemotherapeutic agent for advanced hepatocellular carcinoma (HCC). The aim of the present study was to evaluate the anticancer effect of sorafenib in cancer stem cell‑like cells, such as side population (SP) cells, in HCC and to analyze the signaling pathway for drug‑resistance. To evaluate the anticancer effects of sorafenib, Huh7 and Huh‑BAT cells were treated with sorafenib, fluorouracil (5‑FU), and sorafenib plus 5‑FU. These cells were examined for growth rates, the SP fraction, sphere‑forming efficacy and expression of c‑Jun N‑terminal kinase (JNK) signaling molecules. Sorafenib and 5‑FU treatment decreased growth rates in Huh7 and Huh‑BAT cells; however, the treatments exerted different effects in SP cells and on the expression levels of JNK signaling molecules. Treatment with 5‑FU increased the SP cell number and upregulated the expression of JNK signaling molecules. By contrast, sorafenib decreased the SP cell number and downregulated the expression of JNK signaling molecules. No significant differences in sphere‑forming efficacy were observed subsequent to 5‑FU and sorafenib treatment in Huh7 and Huh‑BAT cells. These results indicate that sorafenib exerted anticancer effects in HCC and SP cells by targeting JNK signaling.

[1]  M. Colombo,et al.  VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE‐1 study , 2014, International journal of cancer.

[2]  B. Sarkadi,et al.  Regulation of the Function of the Human ABCG2 Multidrug Transporter by Cholesterol and Bile Acids: Effects of Mutations in Potential Substrate and Steroid Binding Sites , 2014, Drug Metabolism and Disposition.

[3]  T. Deng,et al.  Positive correlation of Oct4 and ABCG2 to chemotherapeutic resistance in CD90(+)CD133(+) liver cancer stem cells. , 2013, Cellular reprogramming.

[4]  J. Zhang,et al.  Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  T. Florio,et al.  Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures , 2013, Cell cycle.

[6]  Stephanie Ma.  Biology and clinical implications of CD133(+) liver cancer stem cells. , 2013, Experimental cell research.

[7]  Kwangmo Yang,et al.  The combination of sorafenib and radiation preferentially inhibits breast cancer stem cells by suppressing HIF-1α expression , 2013, Oncology reports.

[8]  C. Tiribelli,et al.  Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma , 2012, BMC Gastroenterology.

[9]  Y. Suh,et al.  c-Jun N-terminal kinase has a pivotal role in the maintenance of self-renewal and tumorigenicity in glioma stem-like cells , 2012, Oncogene.

[10]  Yanlei Li,et al.  Characterization of sphere-forming cells with stem-like properties from the small cell lung cancer cell line H446. , 2012, Cancer letters.

[11]  Michael Karin,et al.  A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. , 2012, Gastroenterology.

[12]  C. Bartolozzi,et al.  Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma , 2012, Cancer Chemotherapy and Pharmacology.

[13]  L. Hui,et al.  Mitogen-activated protein kinases in hepatocellular carcinoma development. , 2011, Seminars in cancer biology.

[14]  B. Spencer‐Dene,et al.  JNK signalling modulates intestinal homeostasis and tumourigenesis in mice , 2009, The EMBO journal.

[15]  W. Thasler,et al.  JNK inhibition sensitises hepatocellular carcinoma cells but not normal hepatocytes to the TNF-related apoptosis-inducing ligand , 2008, Gut.

[16]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[17]  L. Lang.  FDA approves sorafenib for patients with inoperable liver cancer. , 2008, Gastroenterology.

[18]  S. Wilhelm,et al.  Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. , 2006, Cancer research.

[19]  R. Pazdur,et al.  Sorafenib for the Treatment of Advanced Renal Cell Carcinoma , 2006, Clinical Cancer Research.

[20]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[21]  M. Goodell.  Multipotential stem cells and 'side population' cells. , 2002, Cytotherapy.

[22]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[23]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.